CENCORA, INC. FY 2025 10-K, explained in plain English
Key financials — as reported
| Total revenue | $321.3B |
| Gross margin | 3.6% |
| Operating income | $2.6B |
| Net income | $1.6B |
| Diluted EPS | $7.96 |
| Cash & equivalents | $4.4B |
| Total assets | $76.6B |
| Long-term debt | $7.7B |
Key takeaway
Cencora reported $321.3 billion in fiscal 2025 revenue but operated on a thin 3.6% gross margin typical of pharmaceutical distribution.
🔒 4 more takeaways in the full analysis
Beneath the surface
The $723.9 million PharmaLex goodwill impairment (GoodwillImpairmentLoss) materially depressed operating income and reflects a strategic misstep in the life sciences services expansion.
🔒 4 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 8 more findings — plus insider trades, activist stakes, and 8-K events for COR.
Read the full analysis free Free account · 5 full analyses included · no card required